Background: The aim of the present study is to evaluate and validate the PSDSS score as a prognostic tool in patients with stage IIIC-IV epithelial ovarian cancer (EOC) who are treated with a first cytoreduction with peritonectomy procedures and HIPEC, and to discuss the usefulness and applicability of this approach in decision making in clinical practice.
Patients And Methods: We analyzed a consecutive series of patients with stage IIIC-IV epithelial ovarian cancer treated by cytoreductive surgery and HIPEC between January 2012 and December 2016.
Results: A total of 115 consecutive patients diagnosed of stage IIIC-IV EOC were included. After the multivariate analyses, the impossibility of performing a complete cytoreduction (CC-score = 1, HR: 4.56, p = 0.012), the PSDSSov (III-IV, HR: 3.59, p = 0.024), a high (>20) PCI (HR: 3.16, p = 0.032), and the histological type of the tumor (G3, HR: 2.28, 95% CI: 1.14-8.14, p = 0.033) were factors that were independently related with lower DFS. Other variables included in PSDSSov such as pathological lymphadenopathy and the clinical symptoms were not independently related to lower DFS in our series.
Conclusions: PSDSSov is a useful tool in the prognostic stratification of patients with advanced ovarian cancer with peritoneal dissemination (IIIB/IIIC).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.suronc.2018.11.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biological and clinical characteristics of non-small cell lung cancer non-specific subtype.
Heliyon
November 2024
The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine,National Clinical Research Center for Respiratory Disease,State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, 510000, China.
Background: Non-small cell lung cancer-not otherwise specified (NSCLC-NOS) is a rare subtype of NSCLC that cannot be classified specifically based on morphology and/or special staining. This study aimed to explore the clinical features, biological and pathological characteristics, treatment, and prognosis of NSCLC-NOS.
Methods: This retrospective study included NSCLC-NOS patients diagnosed and treated between 2010 and 2022.
Gastric SMARCA4-Deficient Undifferentiated Carcinoma: A Report of 4 Patients and Literature Review.
Int J Surg Pathol
November 2024
Department of Pathology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Zhejiang Province, China.
SMARCA4-deficient undifferentiated carcinoma (SMARCA4-DUC) of the stomach is a rare gastric tumor that has been receiving increased attention in recent years. With its varied pathological presentations, accurate diagnosis can be challenging. In order to improve our understanding of this aggressive neoplasm, we have carefully documented and analyzed 4 patients with gastric SMARCA4-DUC, adding to the overall knowledge of this uncommon malignancy.
View Article and Find Full Text PDFGermline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
Br J Cancer
December 2024
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Background: High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm's chemotherapy response score (CRS). We investigated whether germline BRCA1/2 (gBRCA1/2) genotype associated with omental CRS phenotype.
View Article and Find Full Text PDFThe challenge of ovarian cancer care in the oldest old.
Cancer Epidemiol
November 2024
Côte d'Or Breast and Gynecological Cancer Registry, George-François Leclerc Cancer Centre, Dijon, France; Epidemiology and Quality of Life Research Unit, INSERM U1231, George-François Leclerc Cancer Centre, Dijon, France.
Introduction: Ovarian cancer (OC) is the eighth most common cancer in women, with a poor prognosis, particularly in older women. The aim of this study was to describe an octogenarian population with OC and to examine the differences in net survival (NS) according to age.
Material And Methods: In this retrospective observational population-based study from a gynecological cancer registry, patients aged > 18 years with an identified epithelial ovarian cancer stage IA to IVB diagnosed between 1998 and 2018 were included.
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.
BMC Cancer
October 2024
The University of Manchester, The Christie NHS Foundation Trust, Manchester, UK.
Background: Anti-angiogenic, VEGF inhibitors (VEGFi) increase progression-free survival (PFS) and, in some cases, overall survival in many solid tumours. However, their use has been compromised by a lack of informative biomarkers. We have shown that plasma Tie2 is the first tumour vascular response biomarker for VEGFi in ovarian, colorectal and gall bladder cancer: If plasma Tie2 concentrations do not change after 9 weeks of treatment with a VEGFi, the patient does not benefit, whereas a confirmed reduction of at least 10% plasma Tie2 defines a vascular response with a hazard ratio (HR) for PFS of 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!